Compound 1 Non-D2 Antipsychotic Therapy for Reduced Side Effects
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Developing non-D2 antipsychotic therapies that are both safe and effective for treating neurological and psychiatric diseases such as schizophrenia has been challenging due to the serious side effects associated with existing D2 dopamine receptor-targeting drugs.
Innovation Solution
The use of Compound 1, an antipsychotic agent with a non-direct-D2 mechanism of action, which minimizes adverse events by targeting trace amine associated receptor-1 (TAAR1) and 5HT1A receptors, thereby reducing the risk of adverse events typically associated with D2 dopamine receptor-affinity drugs.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If D2 dopamine receptor-targeting drugs are used to treat neurological and psychiatric disorders, then therapeutic efficacy is improved, but serious side effects and adverse events increase
Solution Approach 1:
The patent changes the mechanism of action parameter from D2 dopamine receptor antagonism to TAAR1 agonism, fundamentally altering how the drug achieves therapeutic effects. This parameter change enables the drug to maintain efficacy while avoiding the harmful side effects associated with D2 receptor blockade, such as extrapyramidal symptoms and metabolic disturbances
Solution Approach 2:
The patent introduces TAAR1 as an intermediary mechanism between the drug and the ultimate therapeutic effect. Instead of directly blocking D2 receptors, the drug activates TAAR1, which then mediates downstream effects that achieve antipsychotic efficacy through a different pathway, thereby avoiding direct interaction with the problematic D2 receptor
2Object-affected harmful factors
If non-D2 antipsychotic therapies are developed to reduce side effects, then safety is improved, but therapeutic efficacy becomes uncertain
Solution Approach 1:
The patent leverages the endogenous trace amine system that naturally regulates dopamine release. By activating TAAR1, the drug harnesses the body's own regulatory mechanisms to achieve therapeutic effects, ensuring that the treatment works through a physiologically relevant pathway that maintains efficacy while improving safety
3Object-affected harmful factors
If decades of research on non-D2 mechanisms are conducted, then safety potential is improved, but clinical readiness and confidence in efficacy remain insufficient
Solution Approach 1:
The patent incorporates preliminary clinical data from Phase 2 trials that demonstrate both efficacy and safety in humans. This preliminary validation provides the confidence and clinical readiness that decades of preclinical research alone could not achieve, bridging the gap between theoretical safety potential and proven clinical effectiveness
Data Source
AI summary
The present disclosure relates to methods of treating neurological or psychiatric diseases or disorders, such as schizophrenia. Compound 1, or a pharmaceutically acceptable salt thereof, is an antipsychotic agent with a non-D2 mechanism of action. Adverse events associated with antipsychotic agents that target the D2 dopamine receptor can be reduced by treating disorders with Compound 1, or a pharmaceutically acceptable salt thereof.